[A23-25] Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V
Last updated 03.07.2023
Project no.:
A23-25
Commission:
Commission awarded on 30.03.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Children's and adolescents' health
Indication:
Children with severe atopic dermatitis, 6 months to 5 years old, who are candidates for systemic therapy
Result of dossier assessment:
- Children whose clinical picture is sufficiently similar to that of adults: hint of a non-quantifiable added benefit
- Children whose clinical picture is not sufficiently similar to that of adults: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.